Cost Of Reviewing Drugs With AI Is ‘Prohibitive’ For US FDA

 
• By Sarah Karlin-Smith
Super Computer
The FDA lacks the necessary funding to review applications with AI and machine learning. • Source: Shutterstock

More from AI

More from Advanced Technologies